10-Q: Rein Therapeutics Lifts LTI-03 Hold, Faces Funding Crisis
Sentiment:
Quarterly Report
Rein Therapeutics announced the FDA lifted the clinical hold on its lead IPF candidate LTI-03, but disclosed substantial doubt about its ability to continue as a going concern past December 2025 without additional funding.
Delay expectedClinical development of LTI-01 is temporarily delayed since June 2024, and in Q4 2024, it was determined this delay may not be a short-term measure, pending additional funds.The Phase 2 RENEW trial of LTI-03 was placed on clinical hold by the FDA on June 10, 2025, pausing enrollment and patient dosing, causing a delay in the trial's progress until the hold was lifted on October 29, 2025.
Capital raiseThe company explicitly states it 'will need additional capital to fund our operations' and 'plans to seek to raise additional funds through equity or debt financings, strategic collaborations, licensing arrangements or other sources.'Entered into a Pre-Paid Advance Agreement (PPA) with Yorkville in July 2025, allowing requests for up to $6.0 million in pre-paid advances over 12 months, with $3.0 million drawn as of October 23, 2025.Entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville in July 2025, allowing the sale of up to $15.0 million of common stock over a 36-month period.Entered into an at-the-market offering agreement (Wainwright Sales Agreement) with H.C. Wainwright & Co., LLC in May 2025, to sell up to $13.7 million of common stock (reduced to $8.1 million in July 2025).Completed April 2025 Transactions (Warrant Exercises, Warrant Exchanges, and Private Placement) generating $5.3 million in gross proceeds.
Worse than expectedThe company explicitly states 'substantial doubt about our ability to continue as a going concern' past December 2025.Cash and cash equivalents of $4.0 million as of September 30, 2025, are insufficient to complete the Phase 2 RENEW clinical trial of LTI-03 or maintain current operations past December 2025.LTI-01 clinical development is indefinitely delayed due to funding constraints.Persistent material weaknesses in internal control over financial reporting were identified and continue to exist.
Summary
- Rein Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing novel therapies for fibrosis indications, with lead candidates LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).
- The FDA clinical hold on the Phase 2 RENEW trial of LTI-03, imposed on June 10, 2025, was lifted on October 29, 2025, after the company addressed nonclinical support concerns.
- Patient recruitment for the LTI-03 RENEW trial is expected to resume in late 2025 or early 2026 across approximately 20 U.S. clinical sites and 30 international sites (UK, Germany, Poland, Australia).
- Initial topline data for the LTI-03 RENEW trial is anticipated in the third quarter of 2026.
- Clinical development of LTI-01 has been temporarily delayed since June 2024, and this delay may not be short-term, pending additional funding.
- The company reported a net loss of $5.6 million for the three months ended September 30, 2025, and $17.9 million for the nine months ended September 30, 2025.
- As of September 30, 2025, cash and cash equivalents totaled $4.0 million.
- Existing cash, combined with proceeds from the Pre-Paid Advance Agreement in October 2025, is only sufficient to fund operations into December 2025, raising substantial doubt about the company's ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting persist, including insufficient accounting personnel and lack of evidence over account reconciliation reviews.
- A master services agreement with a CRO for the LTI-03 study, valued at up to $17.0 million, was terminated in August 2025 with no future commitment.
- The exclusive option agreement with Advancium Health Network for the legacy ALRN-6924 compound was terminated in July 2025.
Sentiment
Score: 3
Explanation: While the lifting of the FDA clinical hold on LTI-03 is a crucial positive development, the company's severe liquidity constraints, explicit 'going concern' warning, and the indefinite delay of its second candidate, LTI-01, present substantial financial challenges. The need for immediate and significant capital raises, coupled with persistent internal control weaknesses, indicates a high-risk profile.
Positives
- The FDA lifted the full clinical hold on the Phase 2 RENEW trial of LTI-03 for IPF on October 29, 2025, allowing the study to proceed.
- Authorization was received from the European Medicines Agency (EMA) and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate the Phase 2 RENEW trial for LTI-03 in Germany, Poland, and the UK.
- Net loss decreased to $5.6 million for the three months ended September 30, 2025, compared to $5.8 million for the same period in 2024.
- Net loss for the nine months ended September 30, 2025, decreased to $17.9 million, compared to $21.9 million for the same period in 2024.
- Research and development expenses decreased by $2.0 million in Q3 2025 compared to Q3 2024, and by $1.9 million for the nine months ended September 30, 2025, compared to the same period in 2024.
Negatives
- Substantial doubt exists about the company's ability to continue as a going concern past December 2025.
- Cash and cash equivalents of $4.0 million as of September 30, 2025, are insufficient to complete the LTI-03 Phase 2 RENEW clinical trial or maintain current operations past December 2025.
- Clinical development of LTI-01 is indefinitely delayed until additional funds are raised.
- The FDA had previously placed a full clinical hold on the LTI-03 RENEW trial on June 10, 2025, due to inadequate nonclinical support.
- The accumulated deficit reached $369.3 million as of September 30, 2025.
- Material weaknesses in internal control over financial reporting persist, including insufficient accounting personnel and lack of evidence over account reconciliation reviews.
- A master services agreement for LTI-03 with a CRO, valued at up to $17.0 million, was terminated in August 2025, indicating a potential change in trial strategy or cost management.
- The exclusive option agreement for ALRN-6924 with Advancium was terminated in July 2025, removing a potential source of future payments.
- General and administrative expenses increased by $1.5 million in Q3 2025 compared to Q3 2024, primarily due to professional fees related to restricted stock units and the Yorkville Transactions commitment fee.
Risks
- Inability to secure sufficient additional capital in the near term to alleviate substantial doubt about the ability to continue as a going concern.
- Inability to fund operating expenses, planned activities, and capital expenditure requirements with current cash, cash equivalents, and investments.
- Risks associated with the unproven approach to drug research and development in fibrotic diseases, particularly Caveolin-1 (Cav1) related peptides, and the ability to develop marketable products.
- Potential for future clinical trial failures for LTI-03 and LTI-01, including challenges in patient enrollment and timing of results.
- Inability to obtain and maintain marketing approvals for LTI-03 and LTI-01.
- Reliance on third-party manufacturing and supply vendors and contract research organizations (CROs).
- Impact of general economic conditions, including inflation and trade restrictions.
- Material weaknesses in internal controls over financial reporting could lead to material misstatements in financial statements.
- Future capital requirements are substantial and depend on various factors, including the scope, timing, and costs of development and regulatory approvals.
- Dilution to existing stockholders if additional funds are raised through equity or convertible preferred stock.
- Increased fixed payment obligations and covenants if debt financing is pursued.
- Relinquishing significant rights or granting unfavorable licenses if funds are raised through strategic collaborations.
- Adverse impact on ability to raise additional funds due to worsening global economic conditions and market volatility.
Future Outlook
The company expects to resume patient recruitment for the LTI-03 RENEW trial in late 2025 or early 2026, with initial topline data anticipated in the third quarter of 2026. It expects to continue incurring operating losses for the foreseeable future and will require substantial additional capital beyond December 2025 to fund operations and complete the LTI-03 trial, planning to seek funds through equity or debt financings, strategic collaborations, or licensing arrangements. Remediation efforts for material weaknesses in internal controls are ongoing and expected to be completed in fiscal year 2025, though no assurance is provided.
Management Comments
- Our future viability is dependent on our ability to raise additional capital to finance our operations.
- Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.
- If additional funds are not available, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts and our business could be materially harmed.
- Management believes that the remediation measures described above will be implemented in a manner such that the controls can be tested, and the identified material weaknesses can be determined to be remediated, however, no assurance can be made that such remediation will occur or that additional material weaknesses will not be identified.
Industry Context
Rein Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on orphan pulmonary and fibrosis indications with significant unmet medical needs. The lifting of the FDA clinical hold on LTI-03 is a critical positive development, allowing the company to advance its lead candidate. However, the indefinite delay of LTI-01 development and the company's explicit 'going concern' warning highlight the severe financial pressures and high-risk nature common for clinical-stage biotech firms heavily reliant on external financing. The various financing activities undertaken reflect typical strategies to sustain operations in this sector, but the short cash runway underscores the precarious financial position.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Deficiency | Material weaknesses identified related to (i) lack of sufficient accounting and supervisory personnel to maintain appropriate segregation of duties and technical accounting experience, (ii) lack of evidence over reviews of account reconciliations and supporting schedules, and (iii) lack of adequate procedures and controls for timely financial statement preparation and review. | Identified as of December 31, 2023, and continued as of September 30, 2025. | Reasonably likely to adversely affect the ability to record, process, summarize, and report financial information, potentially leading to material misstatements. |
Related Party Transactions
- In April 2025, entities affiliated with Bios Partners exchanged PIPE Warrants for Exchange Pre-Funded Warrants, providing $2,079 thousand in cash.
- An entity affiliated with Bios Partners purchased additional Placement Pre-Funded Warrants for $500 thousand in a private placement.
Stakeholder Impact
- Shareholders face significant dilution risk from future equity raises and potential for substantial value loss if the company cannot secure funding and continues as a going concern. The lifting of the LTI-03 clinical hold provides a positive clinical update, but is heavily offset by financial instability.
- Employees face uncertainty regarding job security due to the 'going concern' warning and potential for delays or reductions in R&D programs.
- Patients and potential customers for LTI-03 and LTI-01 face the risk of delayed or halted development of these treatment options due to funding constraints.
- Creditors face increased risk due to the 'going concern' warning and the company's reliance on future financing.
- Suppliers and Contract Research Organizations (CROs) face the risk of delayed or non-payment if funding is not secured, as evidenced by the termination of a $17.0 million CRO agreement.
Next Steps
- Resume patient recruitment for the LTI-03 RENEW trial in late 2025 or early 2026 in the U.S., UK, Germany, Poland, and Australia.
- Obtain additional funding through equity or debt financings, strategic collaborations, licensing arrangements, or other sources to continue operations beyond December 2025 and complete the LTI-03 trial.
- Continue implementing procedures to remediate material weaknesses in internal control over financial reporting, including hiring additional accounting personnel and engaging third-party specialists.
- Expect initial topline data for the LTI-03 RENEW trial in the third quarter of 2026.
- Rients LLC will evaluate the legacy ALRN-6924 compound.
Key Dates
| Date | Description |
|---|---|
| August 2006 | Company entered into an exclusive license agreement with Harvard and Dana-Farber Cancer Institute. |
| February 2010 | Harvard/DFCI agreement was amended and restated, adding patent rights and increasing annual license maintenance fees. |
| June 2013 | Company entered into a patent and technology license agreement with UT System, on behalf of UTHSCT. |
| December 2013 | UTHSCT Agreement amended and restated to include certain patents in all fields worldwide. |
| May 2015 | Company entered into a patent license agreement with UT Austin on behalf of UT System. |
| March 2016 | Company entered into a license agreement with Medical University of South Carolina Foundation for Research Development (MUSC). |
| January 2017 | UT Austin 6607 Agreement amended and restated. |
| May 2017 | UTHSCT Agreement amended and restated to modify milestone criteria. |
| March 2018 | Company entered into a license agreement with Vivarta Therapeutics, LLC. |
| September 2018 | MUSC Agreement amended and restated to include definitions of related methods, products, and rights. |
| November 2018 | UT Austin 6607 Agreement amended and restated. |
| June 2019 | UT Austin 6607 Agreement amended and restated. |
| June 15, 2021 | Company's 2021 Stock Incentive Plan approved by stockholders. |
| June 16, 2021 | 2021 Stock Incentive Plan became effective. |
| February 2023 | Company decided to terminate further development of ALRN-6924. |
| October 31, 2023 | Company acquired Lung Therapeutics, Inc. (Lung Acquisition). |
| October 31, 2023 | Company entered into a Stock and Warrant Purchase Agreement (Purchase Agreement) with accredited investors. |
| November 2, 2023 | PIPE Financing closed. |
| March 5, 2024 | 11,957 shares of Series X Preferred Stock automatically converted into 11,957,000 shares of common stock. |
| March 31, 2024 | Expiration of the lease, company now operates virtually. |
| April 7, 2024 | Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2024. |
| May 1, 2024 | Offering Warrants issued. |
| May 3, 2024 | Underwritten follow-on public offering (the Offering) closed. |
| May 8, 2024 | Bios Entities converted 421 shares of Series X Preferred Stock into 421,000 shares of common stock. |
| June 2024 | Company decided to temporarily delay clinical development of LTI-01. |
| July 26, 2024 | Equity distribution agreement with Citizens JMP Securities, LLC. |
| Q4 2024 | Company determined temporary delay of LTI-01 may not be short-term. |
| October 31, 2024 | Company entered into an exclusive option agreement with Advancium Health Network for the sale of ALRN-6924. |
| January 1, 2025 | Company adopted ASU 2024-01. |
| January 10, 2025 | Company amended its Restated Certificate of Incorporation to change its name from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc. |
| January 2025 | Company issued and sold 317,772 shares of common stock pursuant to the Equity Distribution Agreement. |
| April 21, 2025 | Company entered into privately negotiated letter agreements for Warrant Exercises and Warrant Exchanges. |
| April 21, 2025 | Bios Purchaser agreed to purchase additional pre-funded warrants in a private placement. |
| April 24, 2025 | Exercise of PIPE Warrants completed; cash payment for Exchange Pre-Funded Warrants due. Private Placement closed. |
| April 2025 | Company entered into a master services agreement with a third-party CRO for LTI-03 study. |
| May 2025 | Exercise of Offering Warrants completed. |
| May 2025 | Company initiated screening and recruitment of patients in the RENEW Phase 2 clinical trial of LTI-03. |
| May 2025 | Company terminated the equity distribution agreement with Citizens JMP. |
| May 15, 2025 | Company entered into an at-the-market offering agreement (Wainwright Sales Agreement) with H.C. Wainwright & Co., LLC. |
| June 10, 2025 | U.S. FDA advised the company of a clinical hold on the Phase 2 RENEW trial of LTI-03. |
| July 8, 2025 | Company received a formal Clinical Hold Letter from the FDA. |
| July 2025 | Exclusive option agreement with Advancium for ALRN-6924 was terminated. |
| July 29, 2025 | Company entered into a Pre-Paid Advance Agreement (PPA) and a Standby Equity Purchase Agreement (SEPA) with Yorkville. |
| July 29, 2025 | Initial Pre-Paid Advance of $1.0 million purchased by Yorkville. |
| August 2025 | Master services agreement with CRO for LTI-03 was terminated. |
| August 2025 | Company entered into a letter agreement with Rients LLC to evaluate ALRN-6924. |
| September 3, 2025 | Registration statement for resale by Yorkville of shares under SEPA filed with the SEC. |
| September 5, 2025 | Registration statement for resale by Yorkville declared effective by the SEC. |
| September 8, 2025 | Yorkville purchased a second Pre-Paid Advance of $1.0 million. |
| September 24, 2025 | Company issued 1,880,872 shares of common stock to Yorkville, fully settling the initial and second PPAs. |
| September 30, 2025 | End of the reporting period for the 10-Q. |
| October 2025 | Company received authorization from the EMA to initiate Phase 2 RENEW trial in Germany and Poland. |
| October 23, 2025 | Yorkville purchased a third Pre-Paid Advance of $1.0 million. |
| October 29, 2025 | FDA notified the company that it had lifted the full clinical hold on the Phase 2 RENEW trial. |
| October 2025 | Third PPA converted to 846,290 shares of common stock. |
| October 30, 2025 | Company issued 300,000 shares of common stock for vested restricted stock units. |
| November 10, 2025 | 26,286,382 shares of common stock outstanding. |
| November 14, 2025 | Date of signing of the 10-Q report. |
| December 2025 | Estimated period until existing cash and PPA proceeds are exhausted. |
| Late 2025 or early 2026 | Expected resumption of patient recruitment for LTI-03 RENEW trial in the U.S. |
| May 1, 2027 | Expiration date for Offering Warrants. |
| May 2, 2027 | Expiration date for PIPE Warrants. |
| May 20, 2029 | Expiration date for warrants assumed in Lung Acquisition. |
| Third quarter of 2026 | Initial topline data expected for LTI-03 RENEW trial. |
Recommendation
strong sellDespite the positive news of the FDA lifting the clinical hold on LTI-03, the company faces an immediate and severe liquidity crisis, explicitly stating 'substantial doubt about its ability to continue as a going concern' past December 2025. The current cash position is insufficient to complete the lead clinical trial, and the second candidate's development is indefinitely delayed. The persistent material weaknesses in internal controls further compound the operational risks. While the clinical program has a lifeline, the financial runway is critically short, making the stock a high-risk investment with a strong likelihood of significant dilution or even insolvency without immediate and substantial capital infusion on favorable terms, which is not guaranteed.
Keywords
Rein Therapeutics, RNTX, Biopharmaceutical, Clinical-stage, Fibrosis, Idiopathic Pulmonary Fibrosis, IPF, LTI-03, RENEW trial, Clinical hold, FDA, EMA, MHRA, Loculated Pleural Effusion, LPE, LTI-01, Going concern, Capital raise, Pre-Paid Advance Agreement, Standby Equity Purchase Agreement, Yorkville, Internal controls, Drug development, Biotech, Pharmaceutical, Clinical trials, Orphan pulmonary, Cav1, Caveolin-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.